论文部分内容阅读
目的建立荧光原位杂交技术平台,应用FISH技术检测在CML检测BCR/ABL融合基因,探讨FISH技术在在CML中应用的价值。方法应用FISH对BCR/ABL探针进行前期的验证,建立正常阈值,再应用该探针检测CML中BCR/ABL融合基因,进行临床检测评估。结果主要假阳性信号模式的正常阈值为1G1R1F 11%、1G1R2F 2%。75例样本FISH检测出48例阳性,15例经细胞遗传学检测,12例检测结果与FISH结果一致,3例CG为阴性,FISH检测为阳性。结论荧光原位杂交技术应用于临床检测之前应进行探针的前期验证,制定一套规范实验流程,且FISH技术在CML诊断、分型、临床治疗方案的制定、预后的判断以及微小残留病变检测上均有重要的价值。
Objective To establish a fluorescence in situ hybridization (FISH) platform and detect the BCR / ABL fusion gene in CML by FISH and explore the value of FISH in CML. Methods FCR was used to verify the BCR / ABL probe and established the normal threshold. The probe was used to detect BCR / ABL fusion gene in CML for clinical evaluation. Results The normal thresholds for the major false positive signal patterns were 11% for 1G1R1F and 2% for 1G1R2F. Of the 75 cases, 48 were positive by FISH and 15 by cytogenetics. The results of 12 cases were consistent with those of FISH. Three cases of CG were negative and FISH was positive. Conclusion Fluorescence in situ hybridization should be performed prior to clinical testing and a set of standardized experimental procedures should be developed. FISH should be used in the diagnosis, classification, clinical treatment of CML, prognosis and detection of minimal residual disease There are important values.